The price of X4 Pharmaceuticals Inc (NASDAQ:XFOR) shares last traded on Wall Street rose 2.56% to $0.62.
Based on available information, 8 analysts follow X4 Pharmaceuticals Inc (NASDAQ:XFOR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.00, we find $3.00. Given the previous closing price of $0.61, this indicates a potential upside of 391.8 percent. XFOR stock price is now -24.84% away from the 50-day moving average and -52.48% away from the 200-day moving average. The market capitalization of the company currently stands at $103.99M.
Among analysts, 1 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $3.20 as their price target over the next twelve months.
With the price target reduced from $3 to $1, B. Riley Securities Downgraded its rating from Buy to Neutral for X4 Pharmaceuticals Inc (NASDAQ: XFOR).
In other news, Ragan Paula, President and CEO sold 39,906 shares of the company’s stock on Nov 03. The stock was sold for $35,915 at an average price of $0.90. Upon completion of the transaction, the President and CEO now directly owns 836,441 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 01, Chief Financial Officer Mostafa Adam S. sold 230,645 shares of the business’s stock. A total of $168,371 was realized by selling the stock at an average price of $0.73. This leaves the insider owning 80,221 shares of the company worth $49737.02. A total of 24.68% of the company’s stock is owned by insiders.
A candlestick chart of X4 Pharmaceuticals Inc (NASDAQ: XFOR) showed a price of $0.6001 on Tuesday morning. During the past 12 months, X4 Pharmaceuticals Inc has had a low of $0.59 and a high of $2.58. As of last week, the company has a debt-to-equity ratio of 0.86, a current ratio of 5.81, and a quick ratio of 5.81. The fifty day moving average price for XFOR is $0.8271 and a two-hundred day moving average price translates $1.3082 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc (NASDAQ: XFOR) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.15 by 0.14. This compares to -$0.26 EPS in the same period last year. The company reported revenue of $27.21 million for the quarter, compared to $20.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.03 percent.
X4 Pharmaceuticals Inc(XFOR) Company Profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
